Ciprofloxacin/Dexamethasone (Ciprodex) otic suspension
Customize your policy alerts
Sign up for Centene Policy CP PMN.248 alerts
Get alerted when Policy CP PMN.248 changes without checking for updates manually.
Monitor payer policy activity
Medical necessity and prior authorization criteria for ciprofloxacin/dexamethasone otic suspension (Ciprodex) for acute otitis media and acute otitis externa across Centene lines of business.
For otitis media with tympanostomy tubes, revised oral antibiotic requirement to systemic antibiotic.
Clarified that generic requirement applies to brand Ciprodex requests; member must use generic ciprofloxacin/dexamethasone otic suspension unless contraindicated or adverse effects.
Coverage Criteria for Ciprofloxacin/Dexamethasone (Ciprodex) Otic Suspension
Initial Approval (Acute Otitis)
Covered when ALL of the following are met:
Policy text lists '26 months' though FDA references 6 months; reconcile at authorization.
Recent systemic antibiotic use defined as within last 3 months.
Non‑FDA approved indications for ciprofloxacin/dexamethasone otic suspension are not authorized under this policy unless the provider submits sufficient documentation demonstrating the efficacy and safety of the requested off‑label use. Such documentation should follow the applicable off‑label use policies: HIM.PA.154 for Health Insurance Marketplace members and CP.PMN.53 for Medicaid, or be consistent with the member's evidence of coverage.
Ciprofloxacin/dexamethasone otic suspension is contraindicated in patients with a history of hypersensitivity to ciprofloxacin, to other quinolones, or to any component of Ciprodex. Additionally, use is contraindicated for viral infections of the external auditory canal (for example, herpes simplex infections) and for fungal otic infections.
Coverage determinations for ciprofloxacin/dexamethasone otic suspension are subject to all terms, conditions, exclusions, and limitations of the member's coverage documents (for example, evidence of coverage, certificate of coverage, policy or contract). State and federal requirements and Health Plan administrative policies and procedures may also affect coverage; compliance with those documents and requirements is required.
For treatment of acute otitis, re‑authorization is not permitted. Members must meet the initial approval criteria for any subsequent coverage; continuation beyond the initial approval period is not authorized under this policy.
Coding and Dose Limits
| NDC/HCPCS not specified | No specific CPT/HCPCS/NDC codes provided in this policy. |
Provider Actions, Prior Authorization, and Documentation Requirements
Prior Authorization Required
Prior authorization required. Initial approvals are limited to 14 days (one 7.5 mL bottle). Re‑authorization is not permitted; members must meet initial approval criteria for any new request.
- Initial approval duration: 14 days (1 bottle, ≤7.5 mL).
- Re-authorization: Not permitted — members must meet initial approval criteria for any subsequent requests.
Generic-first and Therapeutic Alternatives
For brand Ciprodex requests, the member must use the generic ciprofloxacin/dexamethasone otic suspension unless contraindicated or clinically inappropriate (e.g., documented allergy to an excipient or clinically significant adverse reaction). Include documentation justifying why the generic is not appropriate when requesting brand.
- Generic-first requirement applies to brand Ciprodex requests.
- If brand is requested, submit documentation demonstrating contraindication or clinical inappropriateness of the generic product.
Required Clinical Documentation
Provider must submit documentation (such as office chart notes, lab results, or other clinical information) supporting that the member has met all approval criteria. Requests lacking sufficient documentation to demonstrate that criteria are met, or requests for non‑FDA indications without adequate off‑label justification, may be denied or returned to the provider.
- Acceptable documentation: office notes, diagnostic test results, medication history, or other clinical information.
- Insufficient documentation or unsupported off‑label use may result in denial or return-to-provider.
Coverage Decisions and Administration
Coverage decisions and the administration of benefits are subject to the terms, conditions, exclusions, and limitations of the member's coverage documents (e.g., evidence of coverage, certificate of coverage, policy/contract), and to applicable state/federal requirements and Health Plan administrative policies and procedures.
- This clinical policy is a guide to medical necessity and does not guarantee payment.
- Always verify member benefits and plan-level coverage determinations before prescribing or dispensing.
Provider Obligations and Policy Use Restrictions
Providers who submit claims or requests for prior authorization are bound by this clinical policy's terms and conditions. Unauthorized copying, use, or distribution of this clinical policy is prohibited. By providing services to members and/or submitting claims for payment, providers, members, and their representatives agree to be bound by these terms.
- Providers remain responsible for exercising independent medical judgment and for maintaining required documentation.
- Unauthorized copying/use/distribution of this clinical policy is strictly prohibited.
Background and Drug Information
Ciprodex is an otic suspension combining the fluoroquinolone antibacterial ciprofloxacin 0.3% with the corticosteroid dexamethasone 0.1% in a 7.5 mL bottle. The product is FDA‑labeled for treatment of acute otitis media in pediatric patients with tympanostomy tubes and for acute otitis externa in patients aged 6 months and older; the typical otic dosing is to instill 4 drops twice daily for 7 days.
Definitions and Key Terms
Revision History and Policy Changes
Clinical policy effective date; material operational changes include clarification that generic ciprofloxacin/dexamethasone otic suspension is required for brand Ciprodex requests unless contraindicated, and wording revised to require systemic (oral) antibiotic use for otitis media with tympanostomy tubes.
Clarified that generic requirement applies to brand Ciprodex requests: member must use generic ciprofloxacin/dexamethasone otic suspension unless contraindicated or adverse effects occur.
Revised oral antibiotic requirement wording for otitis media with tympanostomy tubes to specify systemic antibiotic use within the prior 3 months.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.